Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 16/20 | 1.00 |
| ▸ | ESR1 | P03372 | 2/20 | 0.70 |
| ▸ | AR | P10275 | 2/20 | 0.70 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.70 |
| ▸ | SHBG | P04278 | 2/20 | 0.70 |
| ▸ | SERPINA6 | P08185 | 1/20 | 0.70 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5311348 | 1.00 | CYP19A1 (1.00) | CYP19A1ESR1ARESR2SHBG | |
| SCHEMBL5697554 | 1.00 | CYP19A1 (1.00) | CYP19A1ESR1ARESR2SHBG | |
| SCHEMBL5499393 | 0.87 | CYP19A1 (0.77) | CYP19A1ESR1ARESR2SHBG | |
| SCHEMBL9938719 | 0.85 | CYP19A1 (0.74) | CYP19A1ESR1ARESR2SHBG | |
| SCHEMBL4448213 | 0.85 | CYP19A1 (0.74) | CYP19A1ESR1ARESR2SHBG | |
| SCHEMBL5479309 | 0.85 | CYP19A1 (0.74) | CYP19A1ESR1ARESR2SHBG | |
| SCHEMBL5574098 | 0.84 | CYP19A1 (0.73) | CYP19A1ESR1ARESR2SHBG | |
| SCHEMBL5493314 | 0.84 | CYP19A1 (0.73) | CYP19A1ESR1ARESR2SHBG | |
| SCHEMBL1418753 | 0.84 | CYP19A1 (0.73) | CYP19A1ESR1ARESR2SHBG | |
| SCHEMBL10405002 | 0.84 | CYP19A1 (0.72) | CYP19A1ESR1ARESR2SHBG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030232797-A1 | Novel derivatives of androstane and androstene with ascorbic acid and use thereof in treating or preventing various conditions, diseases, and disorders | FORBES MEDI-TECH INC. | 2003-12-18 | — | — | US | disclosed |
| US-4898694-A | 17-Hydroxy-steroids | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 1990-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232797-A1 | Novel derivatives of androstane and androstene with ascorbic acid and use thereof in treating or preventing various conditions, diseases, and disorders | HSD17B11, CYP17A1, CYP27B1 | CYP19A1 17/4885ESR1 126/4885AR 36/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.